Relaxin..., from the Announcement of the breastcancer 1b results.
‘This study is currently in a Phase 2 trial in women with HER2 negative locally advanced breast cancer, and five of the patients in the Phase 1b study qualify for assessment of Phase 2 data. The Phase 2 trial will be in 26 patients using a two stage Simons MinMax Design. If at least three pCRs are observed in the first 11 patients, then the Phase 2 trial expands to another 15 patients. For the purposes of this analysis, two pCRs have already been observed in the first five patients.’
As we know, many sub groups of breastcancers.
The ptx-200 combined trial showed better results for receptor sub group locally advanced.
The phase 2 current trial will aim at quantifying this sub group’s highly efficacy results and also it’s above industry baseline on the triple negative sub group. Worth noting that the triple negative sub group has no receptor element.
So, using my interpretation thus keeping simpler, the discovery on the experiment trials thus far, have our scientific team correlate that the ptx-200 and it’s Akt pathway disruption has greater effect on receptor sub groups of breastcancer response.
If you or others alike want a more clearer understanding of the phenotype verses the genotype understanding, worth a re read of the ‘precision medicine’ announcement by Professor Sebti, early this year.
Hope the helps.
PTX Price at posting:
7.4¢ Sentiment: Buy Disclosure: Held
